Donor-derived HIV-specific T-cells (HST)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Donor-derived HIV-specific T-cells (HST), covering 2025-04-29 to 2025-04-29. Get the full timeline:
Most recent: Clinical Trial Update: Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST) [Phase 1]